当前位置： SCI文献检索 > Applied Health Economics and Health Policy期刊下所有文献 > Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.

Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.

Abstract：

BACKGROUND:Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE:To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn's disease and ulcerative colitis. METHODS:This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs. RESULTS:Median total direct costs and total indirect costs per patient per year in patients with Crohn's disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation. CONCLUSIONS:Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices.

journal_name

Appl Health Econ Health Policy

journal_title

Applied health economics and health policy

authors

Kostić M,Djakovic L,Šujić R,Godman B,Janković SM

doi

10.1007/s40258-016-0272-z

subject

Has Abstract

pub_date

2017-02-01 00:00:00

pages

85-93

issue

1

eissn

1175-5652

issn

1179-1896

pii

10.1007/s40258-016-0272-z

journal_volume

15

pub_type

杂志文章

相关文献

Applied Health Economics and Health Policy文献大全
  • Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.

    abstract：BACKGROUND:Liposomal amphotericin B (L-AMB) and amphotericin B lipid complex (ABLC) are both indicated for treating invasive fungal infections (IFIs) caused by Aspergillus, Candida and Cryptococcus spp. among patients who are refractory to or intolerant of conventional amphotericin B (CAB). Prior studies have suggested...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-013-0072-7

    authors： Yang H,Chaudhari P,Zhou ZY,Wu EQ,Patel C,Horn DL

    更新日期：2014-02-01 00:00:00

  • The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.

    abstract：BACKGROUND:In Slovenia during the period 2000-2010, the number of years of potential life lost before the age of 70 years per 100,000 population under 70 years of age declined 25 %. OBJECTIVE:The aim of this study was to test the hypothesis that pharmaceutical innovation played a key role in reducing premature mortali...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-014-0144-3

    authors： Lichtenberg FR

    更新日期：2015-04-01 00:00:00

  • Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

    abstract：OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-019-00496-1

    authors： Vreman RA,Geenen JW,Hövels AM,Goettsch WG,Leufkens HGM,Al MJ

    更新日期：2019-12-01 00:00:00

  • Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services.

    abstract：BACKGROUND:little is known about the economics of acquiring and processing the more than 14 million units of red blood cells used annually in the US. OBJECTIVE:to determine the average price paid by hospitals to suppliers for a unit of red blood cells and to identify cost variations by region and facility type and siz...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11530740-000000000-00000

    authors： Toner RW,Pizzi L,Leas B,Ballas SK,Quigley A,Goldfarb NI

    更新日期：2011-01-01 00:00:00

  • A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zea

    abstract：OBJECTIVES:Invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) still represent a significant medical burden in children < 5 years of age in New Zealand (NZ), with marked disparities across socio-economic and ethnic groups. This cost-effectiveness evaluation aims to compare the potential impact o...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0387-5

    authors： Varghese L,Talbot L,Govender A,Zhang XH,Mungall BA

    更新日期：2018-06-01 00:00:00

  • Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.

    abstract：BACKGROUND:In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. OBJECTIVE:The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. METHODS:In the MONE...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,随机对照试验

    doi：10.2165/11592220-000000000-00000

    authors： Gazzard B,Hill A,Anceau A

    更新日期：2011-07-01 00:00:00

  • Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use.

    abstract：OBJECTIVES:To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies. METHODS:Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (D...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0440-4

    authors： Kemp-Casey A,Pratt N,Ramsay E,Roughead EE

    更新日期：2019-06-01 00:00:00

  • Inclusion of compliance and persistence in economic models: past, present and future.

    abstract：:Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/BF03261872

    authors： Kadambi A,Leipold RJ,Kansal AR,Sorensen S,Getsios D

    更新日期：2012-11-01 00:00:00

  • The importance of proximity to death in modelling community medication expenditures for older people: evidence from New Zealand.

    abstract：BACKGROUND:Concerns about the long-term sustainability of health care expenditures (HCEs), particularly prescribing expenditures, has become an important policy issue in most developed countries. Previous studies suggest that proximity to death (PTD) has a significant effect on total HCEs, with its exclusion leading to...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-014-0121-x

    authors： Moore PV,Bennett K,Normand C

    更新日期：2014-12-01 00:00:00

  • Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.

    abstract：BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-015-0180-7

    authors： Shields GE,Bates AE,Chapman AM

    更新日期：2015-10-01 00:00:00

  • Listening to the decision makers: sustainability of PBMA in Alberta.

    abstract：BACKGROUND:Decision makers within the Calgary Health Region adopted and applied programme budgeting and marginal analysis (PBMA) for priority-setting activity across major service portfolios within the Region. METHODS:Seventeen in-depth qualitative interviews were conducted with senior managers and clinicians to gain ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/00148365-200403030-00005

    authors： Mitton C,Patten S,Donaldson C

    更新日期：2004-01-01 00:00:00

  • A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

    abstract：BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-015-0183-4

    authors： Campbell JR,Sasitharan T,Marra F

    更新日期：2015-08-01 00:00:00

  • Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

    abstract：BACKGROUND:Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US. OBJECTIVES:The objective of this study was to estimate excess direct costs associated with privately insured PAH patients in the US. METHODS:From a privately ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11592430-000000000-00000

    authors： Kirson NY,Birnbaum HG,Ivanova JI,Waldman T,Joish V,Williamson T

    更新日期：2011-09-01 00:00:00

  • Cost data assessment in multinational economic evaluations: some theory and review of published studies.

    abstract：:This article reviews the concept of costing, and how cost data have been considered and reported in recent multinational economic evaluations. It appears that current practice frequently does not comply with microeconomic foundations and standards for good practice. A number of studies fail to indicate the year of cos...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：

    authors： Halliday RG,Darba J

    更新日期：2003-01-01 00:00:00

  • The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial.

    abstract：BACKGROUND:Chronic obstructive pulmonary disease (COPD) affects approximately 3 million people in the UK. An 8-week pulmonary rehabilitation (PR) course is recommended under current guidelines. However, studies show that initial benefits diminish over time. OBJECTIVE:We present here an economic evaluation conducted al...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40258-015-0199-9

    authors： Burns DK,Wilson EC,Browne P,Olive S,Clark A,Galey P,Dix E,Woodhouse H,Robinson S,Wilson A

    更新日期：2016-02-01 00:00:00

  • Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.

    abstract：BACKGROUND:South Korea is unique in that it leads global markets in R&D as well as production of biosimilar products and was the first market into which some biosimilar products were introduced. We analyzed the time trend of market penetration and simulated saved spending by biosimilars in South Korea. METHODS:We pull...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-019-00547-7

    authors： Lee HJ,Han E,Kim H

    更新日期：2020-08-01 00:00:00

  • Financial risk of the biotech industry versus the pharmaceutical industry.

    abstract：:The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/BF03256149

    authors： Golec J,Vernon JA

    更新日期：2009-01-01 00:00:00

  • The influence of bonus payments to doctors on hospital revenue: results of a quasi-experimental study.

    abstract：:There is wide consensus that the ways in which providers are reimbursed by third parties will affect their behaviour and, hence, the efficient use of limited resources and the performance of health systems. However, there seems to be little evidence on how payment to hospital-based doctors affects hospital performance...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：

    authors： Liu X,Mills A

    更新日期：2003-01-01 00:00:00

  • The impact of rural health care accessibility on cancer-related behaviors and outcomes.

    abstract：BACKGROUND:This research seeks to identify the relationship between economic factors related to the ability to receive and pay for health services and adverse cancer outcomes, as well as preventative screening and behavioral factors that influence the risk of cancer. We focus on the Northern High Plains region, where w...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-014-0099-4

    authors： Belasco EJ,Gong G,Pence B,Wilkes E

    更新日期：2014-08-01 00:00:00

  • Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.

    abstract：:One focus of health economics is the trade-off between limited resources and the (health) needs of a community. Cost-effectiveness analysis (CEA), while being one of the most accepted evaluation methodologies in health economics, does not account for many important costs and benefits of health care interventions. Some...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：

    authors： Bridges JF

    更新日期：2003-01-01 00:00:00

  • Stated Uptake of Physical Activity Rewards Programmes Among Active and Insufficiently Active Full-Time Employees.

    abstract：BACKGROUND:Employers are increasingly relying on rewards programmes in an effort to promote greater levels of activity among employees; however, if enrolment in these programmes is dominated by active employees, then they are unlikely to be a good use of resources. OBJECTIVE:This study uses a stated-preference survey ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-017-0327-9

    authors： Ozdemir S,Bilger M,Finkelstein EA

    更新日期：2017-10-01 00:00:00

  • Does Insurance Status Influence a Patient's Hospital Charge?

    abstract：BACKGROUND:There is obscurity regarding how US hospitals determine patients' charges. Whether insurance status influences a patient's hospital charge has not been explored. OBJECTIVE:The objective of this study was to determine whether hospitals charge patients differently based on their insurance status. METHODS:Thi...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-017-0308-z

    authors： Woodworth L,Romano PS,Holmes JF

    更新日期：2017-06-01 00:00:00

  • SecurAcath for Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance.

    abstract：:Central venous catheters are commonly used to deliver therapies and to monitor patients, and require securing at the point of percutaneous entry to avoid dislodgement. SecurAcath is a catheter securement device designed for central venous catheters. The National Institute for Health and Care Excellence, as a part of i...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-018-0427-1

    authors： Macmillan T,Pennington M,Summers JA,Goddard K,Zala D,Herz N,Peacock JL,Keevil S,Chalkidou A

    更新日期：2018-12-01 00:00:00

  • Level of Evidence in Economic Evaluations of Left Atrial Appendage Closure Devices: A Systematic Review.

    abstract：OBJECTIVES:The objective of the present work was to assess the level of evidence in economic evaluations of percutaneous left atrial appendage closure devices, and to test the complementarity of three different tools for assessing the quality of economic evaluations. METHODS:We conducted a systematic review of article...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0429-z

    authors： Nédellec E,Pineau J,Prognon P,Martelli N

    更新日期：2018-12-01 00:00:00

  • Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.

    abstract：BACKGROUND:Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0442-2

    authors： Wilson L,Turkistani F,Tran DM,Huang W,Lin TK

    更新日期：2019-04-01 00:00:00

  • The use of research abstracts in formulary decision making by the Joint Oncology Drug Review of Canada.

    abstract：BACKGROUND AND OBJECTIVE:Opinions on the use of research abstracts in policy decision making are conflicting. We sought to evaluate the influence of research abstracts in guiding decisions of the Joint Oncology Drug Review of Canada (JODR), which conducts clinical and economic reviews of new cancer treatment drugs for ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11530510-000000000-00000

    authors： Weizman AV,Griesman J,Bell CM

    更新日期：2010-01-01 00:00:00

  • Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance.

    abstract：:The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluat...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-018-0447-x

    authors： Dale M,Morgan H,Carter K,White J,Carolan-Rees G

    更新日期：2019-02-01 00:00:00

  • Association Between Medicare's Mandatory Hospital Value-Based Purchasing Program and Cost Inefficiency.

    abstract：BACKGROUND:The Patient Protection and Affordable Care Act instituted pay-for-performance programs, including Hospital Value-Based Purchasing (HVBP), designed to encourage hospital quality and efficiency. OBJECTIVE AND METHOD:While these programs have been evaluated with respect to their implications for care quality a...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-017-0357-3

    authors： Izón GM,Pardini CA

    更新日期：2018-02-01 00:00:00

  • Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada.

    abstract：BACKGROUND:Although suicide-prevention campaigns have been implemented in numerous countries, Canada has yet to implement a strategy nationally. This is the first study to examine the cost utility of the implementation of a multidimensional suicide-prevention program that combines several interventions over a 50-year t...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-019-00511-5

    authors： Lebenbaum M,Cheng J,de Oliveira C,Kurdyak P,Zaheer J,Hancock-Howard R,Coyte PC

    更新日期：2020-04-01 00:00:00

  • Current and future economic burden of osteoporosis in New Zealand.

    abstract：BACKGROUND:Osteoporosis is recognized as a serious health condition in developed as well as developing countries. There are no accurate estimates of the extent of the burden of osteoporosis in New Zealand. The purpose of this study was to estimate the economic burden of osteoporosis in New Zealand using data from inter...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11531500-000000000-00000

    authors： Brown P,McNeill R,Leung W,Radwan E,Willingale J

    更新日期：2011-03-01 00:00:00